References
- Adams D. D., Kennedy T. H. Evidence to suggest that LATS protector stimulates the human thyroid gland. J. clin. Endocr 1971; 33: 47
- Anderberg B., Ernestrom S., Gillquist J., Smeds S. Protein composition of the human thyroid colloid in patients with hyperthyroidism. J. Endocr, In press
- Anderberg B., Ernestrom S., Gillquist J., Smeds S. Protein composition of the thyroid colloid in euthyroid patients. Acta Endocr, In press
- Biran S., Tal E. Effect of the beta-blocking drug propranolol on the 131I utilization in euthyroid patients. J. Clin. Pharmac 1972; 2: 105
- Björkman U. Studies on the synthesis and transport of iodoproteins in the thyroid gland. Ph.D. Thesis, Göteborg University, Sweden 19773
- Dème D., Pommier J., Gaverat J. M., Nunnez J. Maximal numbers of hormonogenic iodothyrosine residues in thyroglobulin united by thyroid peroxi-dase. Eur. J. Biochem 1976; 70: 7
- Field J. B., Larsen P. R., Yamashita K., Chayoth R. Effect of TSH on iocline metabolism and intermediary metabolism in tissue from patients with Graves' disease. J. clin. Endocr. Metab 1974; 39: 942
- Hadden D. R., Bell T. K., McDevitt D. G., Shanks R. G., Montgomery D. A.D., Weaver J. A. Propranolol and the utilization of radioiocline by the human thyroid gland. Acta Endocr 1969; 61: 393
- Hall R., Smith B. R., Mukhtar E. D. Thyroid stimulators in health and disease. Clin. Endocr 1975; 4: 213
- Izumi M., Larsen P. R. Triiodothyronine, thy-roxine and iocline in purified thyroglobulin from patients with Graves' disease. J. clin. Invest 1977; 59: 1105
- Kendall-Taylor P. Effects of LATS and LATS protector on human thyroid adenyl cyclase activity. Br. med. J 1973; iii: 72
- Levey G. S. The adrenergic nervous system in hyperthyroidism: therapeutic role of beta adrenergic blocking drugs. Pharmacol. & Ther. C 1975; 1: 431
- Lowry O. H., Rosebrough M. H., Farr A. L., & Randall. R.J. Protein measurement with the folin reagent. J. Biol. Chem 1951; 193: 265
- McKenzie J. M., Zakarija M. A reconsideration of a thyroid-stimulating immunoglobulin as the cause of hyperthyroidism in Graves' disease. J. clin. Endocr. Metab 1976; 42: 778
- Nadler N. J., Young B. A., Leblond C. P., Mitmaker B. Elaboration of thyroglobulin in the thyroid follicle. Endocrinol 1964; 74: 333
- Nilsson O. R., Almqvist S., Karlberg B. E., Kågedal B., Tegler L. Non-selective and selective-beta-1 adrenoceptor blocking agents in the treatment of hyperthyroidism. Acta med. Scand, In press
- Onaya T., Kotani M., Yamada T., Ochi Y. New in vitro tests to detect the thyroid stimulator in sera from hyperthyroid patients by measuring colloid droplet formation and cyclic AMP in human thyroid slices. J. clin. Endocr. Metab 1973; 36: 859
- Orgiazzi J., Chopra L. J., Williams D. E., Solomon D. H. Evidence for normal thyroidal adenylate cyclase, cyclic AMP-bincling and protein-kinase activities in Graves' disease. J. clin. Endocr. Metab 1975; 40: 40
- Schneider P. B. TSH stimulation of 32P incorporation into phospholipids of thyroids from patients with Graves' disease. J. clin. Endocr. Metab 1974; 38: 148
- Schneider W. C. Phosphorous compounds in animal tissues; extraction and estimation of desoxy-pentose nucleic acid and of pentose nucleic acid. J. biold. Chem 1945; 161: 293
- Shanks R. G., Hadden D. R., Lowe D. C., McDevitt D. G., Montgomery D. A.D. Controlled trial of propranolol in thyrotoxicosis. Lancet 1969; i: 993
- Shishiba Y., Shimizu T., Yoshimura S., Shizume K. Direct evidence for human thyroidal stimulation by LATS-protector. J. clin. Endocr. Metab 1973; 36: 517
- Solomon D. H., Chopra I. J. Graves' disease-1972. Mayo clin. Proc 1972; 47: 803
- Tarutani O., Kondo T., Horiguchi-Sho K. The effect of iodide administration on hog thyroid gland and the composition of thyroglobulin and 27–S iodoprotein. Endocrinol. Japon. 1975; 22: 389
- Valenta L. J. Thyroid peroxidase, thyroglobulin, CAMP and DNA in human thyroid. J. clin. Endocr. Metab 1976; 43: 466
- Wartofsky L., Dirnond R. C., Noel G. L., Frantz A. G., Earll J. M. Failure of propranolol to alter thyroid iocline release, thyroxine turnover, or the TSH and PRL responses to thyrotropin-releasing hormone in patients with thyrotoxicosis. J. clin. Endocr. Metab 1975; 41: 485